Optical Coherence Tomography And NEphropathy: The OCTANE Study
Launched by UNIVERSITY OF EDINBURGH · May 2, 2014
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The OCTANE Study is a clinical trial designed to learn more about how high blood pressure and chronic kidney disease affect blood vessels in the body. Researchers are using a special test called Optical Coherence Tomography (OCT), which is a simple and quick way to take pictures of the blood vessels in the back of the eye. They want to see if OCT can spot changes in these blood vessels in patients with hypertension and chronic kidney disease, compared to healthy individuals. Additionally, the study aims to find out if these changes improve with treatment.
To participate in the trial, individuals need to be between 18 and 80 years old, have a body mass index (BMI) of 35 or less, and either have high blood pressure or chronic kidney disease. Participants can expect to undergo the OCT test during the study, which is non-invasive and does not require any surgery. It's important to note that certain factors may exclude someone from participating, such as having serious eye diseases, recent blood donation, or being part of another clinical trial. This study is currently recruiting, and it could provide valuable insights into how managing blood pressure and kidney health can benefit overall vascular health.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male or female
- • Age 18-80
- • Body mass index ≤35
- • For those with hypertension: BP ≥140/90 or on treatment for hypertension
- • For those with CKD: CKD as defined by the Kidney Diseases Quality Initiative guidelines
- Exclusion Criteria:
- • Subject is below the age of legal consent, or is mentally or legally incapacitated
- • The subject has donated blood (450 ml) within the last 4 weeks
- • Past or present drug or alcohol abuse including intravenous drug abuse at any time
- • Participation in another clinical trial within 1 month
- • Considered to be at high risk of HIV or hepatitis B
- • Patients with known eye disease, or previous eye surgery, or refractive error greater than +/- 6 dioptres.
About University Of Edinburgh
The University of Edinburgh, a prestigious institution renowned for its commitment to research excellence and innovation, serves as a leading clinical trial sponsor dedicated to advancing healthcare through rigorous scientific inquiry. With a strong emphasis on multidisciplinary collaboration, the university facilitates cutting-edge clinical studies that aim to explore novel therapies and improve patient outcomes. Leveraging its extensive network of researchers, healthcare professionals, and state-of-the-art facilities, the University of Edinburgh is at the forefront of translating scientific discoveries into practical applications, thereby contributing significantly to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Edinburgh, Midlothian, United Kingdom
Patients applied
Trial Officials
Neeraj Dhaun, MD PhD
Principal Investigator
University of Edinburgh
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials